Finally, confirmatory validation of the proposed downstream pathways—particularly the direct activation mechanism of the PI3K/AKT pathway and the role of TRIM44 in inducing epithelial-mesenchymal transition (EMT) in bladder cancer—has become the core focus of our current research. The gene discussed is AKT1; the disease is urinary bladder cancer.